Analysts Issue Forecasts for Stoke Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities researchers at Leerink Partnrs issued their Q2 2024 earnings per share estimates for shares of Stoke Therapeutics in a research note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst R. Li expects that the company will post earnings of ($0.43) per share for the quarter. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.28) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics' Q3 2024 earnings at ($0.48) EPS, FY2027 earnings at ($1.90) EPS and FY2028 earnings at ($0.05) EPS.

Several other research firms have also weighed in on STOK. TD Cowen raised Stoke Therapeutics from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 26th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Thursday. Canaccord Genuity Group lifted their price objective on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Tuesday, March 26th. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday, March 26th. Finally, Wedbush lifted their price target on Stoke Therapeutics from $13.00 to $17.00 and gave the stock an "outperform" rating in a report on Tuesday, March 26th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $19.63.

Stoke Therapeutics Stock Down 5.4 %

Shares of NASDAQ:STOK traded down $0.73 during midday trading on Friday, reaching $12.77. The company had a trading volume of 526,719 shares, compared to its average volume of 961,458. The business's 50 day moving average price is $7.85 and its 200 day moving average price is $5.64. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $16.40. The stock has a market cap of $591.25 million, a PE ratio of -5.30 and a beta of 0.77.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in STOK. Ensign Peak Advisors Inc acquired a new stake in Stoke Therapeutics in the first quarter valued at $25,000. Point72 Hong Kong Ltd bought a new position in shares of Stoke Therapeutics during the first quarter worth about $27,000. Great West Life Assurance Co. Can lifted its stake in shares of Stoke Therapeutics by 46.7% in the first quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company's stock worth $28,000 after acquiring an additional 1,078 shares during the period. Dorsey & Whitney Trust CO LLC bought a new stake in Stoke Therapeutics in the third quarter valued at approximately $43,000. Finally, UBS Group AG bought a new stake in Stoke Therapeutics in the third quarter valued at approximately $47,000.

Insider Activity

In other news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the sale, the chief financial officer now directly owns 20,746 shares of the company's stock, valued at approximately $126,550.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the sale, the chief financial officer now owns 20,746 shares in the company, valued at approximately $126,550.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Edward M. Md Kaye sold 11,150 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the transaction, the chief executive officer now directly owns 69,350 shares in the company, valued at $423,035. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,741 shares of company stock worth $223,115. Corporate insiders own 12.30% of the company's stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.